Patheon opens Milton Park early phase development centre
Canadian company Patheon, a global provider of drug development and manufacturing services, has officially opened a new early phase development facility located in Milton Park in Oxfordshire, UK.
Canadian company Patheon, a global provider of drug development and manufacturing services, has officially opened a new early phase development facility located in Milton Park in Oxfordshire, UK.
The 1,250m2 leased development facility contains newly constructed formulation laboratories and a fully equipped analytical laboratory. It holds an Investigational Medical Product License from the MHRA (UK) and is already working on a number of development projects.
Milton Park operations will focus on the early phase development of solid, semi-solid and oral liquid dosage forms. The facility includes GMP manufacturing areas for the production of clinical trial materials for Phase I/II trials. Patheon's Quick To Clinic programmes, which accelerate molecules to clinical trials while minimising API requirements, will be supported at the site.
"The Milton Park facility was created to meet our customers' growing demand for rapid early phase development capacity in a strategic location," said Norman Barras, vice president, pharmaceutical development services, Europe. "We believe that our Quick to Clinic approach will provide a valuable opportunity to shorten the development times of our customers' projects."